Boland Miriam, Higgins Agnes, Kwak Sookyung, Cadogan Cathal
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.
School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.
Health Expect. 2025 Aug;28(4):e70384. doi: 10.1111/hex.70384.
Despite significant increases in the prescribing of psychiatric medication in recent years, many uncertainties exist regarding the process of reducing and stopping these medications. A James Lind Alliance Priority Setting Partnership (PSP) study was conducted to identify the top 10 research priorities on reducing and stopping psychiatric medication. As part of the PSP study, an online survey was conducted, which asked respondents to submit their views and experiences of reducing and/or stopping psychiatric medication as free-text comments. This study aimed to conduct a descriptive analysis on these free-text survey responses.
A qualitative descriptive analysis was undertaken on responses submitted to the online survey, which was disseminated using social media, newsletters and emails. Responses were submitted by three stakeholder groups (i.e., people with lived experience of taking and/or stopping psychiatric medication, family members/carers/supporters and healthcare professionals). All survey responses were downloaded, screened and analysed using template analysis. A coding template was iteratively developed using samples of responses and then applied to the responses by the researchers working independently.
In total, 705 responses contained free-text additional comments, of which 483 responses were considered in-scope. Six main themes were identified: (1) experiences of psychiatric medication, (2) challenges to reducing/stopping psychiatric medication, (3) strategies used to reduce/stop psychiatric medication, (4) outcomes of reducing/stopping psychiatric medication, (5) emotional context and (6) areas for improvement.
This study identified numerous challenges faced by respondents when discontinuing psychiatric medication, the uncertainty that prevails in terms of the best tapering strategy and the emotional impact of taking and/or stopping psychiatric medication. The findings also highlight the importance of support during the discontinuation process, in particular psychosocial supports, and areas that could be targeted to improve the withdrawal process.
An international Steering Group was established to oversee and guide the PSP study in accordance with the James Lind Alliance guidance and Patient and Public Involvement principles. Patient and public groups were represented on the Steering Group and were among the three key stakeholder groups (i.e., people with lived experience of taking and/or stopping psychiatric medication, family members/carers/supporters and healthcare professionals) engaged with throughout.
尽管近年来精神科药物的处方量显著增加,但在减少和停用这些药物的过程中仍存在许多不确定性。开展了一项詹姆斯·林德联盟优先事项设定合作项目(PSP)研究,以确定减少和停用精神科药物的前10大研究重点。作为PSP研究的一部分,进行了一项在线调查,要求受访者以自由文本评论的形式提交他们减少和/或停用精神科药物的观点和经历。本研究旨在对这些自由文本调查回复进行描述性分析。
对通过社交媒体、时事通讯和电子邮件分发的在线调查所收到的回复进行定性描述性分析。回复由三个利益相关者群体提交(即有服用和/或停用精神科药物亲身经历的人、家庭成员/护理人员/支持者以及医疗保健专业人员)。所有调查回复均被下载、筛选,并使用模板分析法进行分析。使用回复样本迭代开发编码模板,然后由独立工作的研究人员将其应用于回复。
总共705条回复包含自由文本附加评论,其中483条回复被视为有效范围。确定了六个主要主题:(1)精神科药物的使用经历,(2)减少/停用精神科药物的挑战,(3)用于减少/停用精神科药物的策略,(4)减少/停用精神科药物的结果,(5)情感背景,以及(6)改进领域。
本研究确定了受访者在停用精神科药物时面临的众多挑战、最佳减量策略方面普遍存在的不确定性以及服用和/或停用精神科药物的情感影响。研究结果还强调了停药过程中支持的重要性,特别是心理社会支持,以及可针对改进停药过程的领域。
成立了一个国际指导小组,以根据詹姆斯·林德联盟的指导方针和患者及公众参与原则监督和指导PSP研究。患者和公众团体在指导小组中有代表,并且是整个过程中参与的三个关键利益相关者群体之一(即有服用和/或停用精神科药物亲身经历的人、家庭成员/护理人员/支持者以及医疗保健专业人员)。